Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

2.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

3.

Radioligand Therapy Set to Transform Oncology Care

4.

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

5.

I Watched My Friend Choose Death. Physician-Assisted Suicide Needs More Guardrails.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot